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INTRODUCTION 
The mammalian hormone melatonin is secreted by the pineal gland mainly during the dark phase of the 
circadian sleep-wake cycle. Its effects have been examined by many authors (1,2) for many years in 
order to determine the role melatonin plays in reproduction and related processes. Recent experiments 
involving mice have shown that nightly administration of melatonin delays the aging process and 
preserves aspects of their youthful state ( 3). One of the main effects melatonin has in the body is to 
suppress the gonadal function acting at different levels on the hypothalamo-pituitary-gonadal system (4). 
Transgenic mice carrying the ectopic gene ofbGH or hGH have a shortened life spans and have 
significantly higher elevated corticosterone levels in serum as compared to normal mice(5). It has 
therefore been hypothesized that cortocosterone, among other steroids, may contribute to the accelerated 
aging process in these transgenic mice. With the above information in mind, we will determine the 
effects, if any, melatonin has on the aging process of both normal and transgenic lines of mice by 
administering exogenous melatonin during the dark phase of the circadian sleep-wake cycle and then 
measuring testosterone and corticosterone blood plasma levels upon completion of the study. We feel 
that this experiment will lead to a better understanding of the role melatonin plays in the aging process. 
MATERIALS AND METHODS 
Transgenic (PEPCK- bGH, PEPCK- hGH) and normal lines of male mice were fed standard mouse 
chow and were housed 4-7 per cage. The housing quarters followed a light/dark cycle of 12:12 with 
darkness lasting from 6 p.m. to 6 a.m. All mice were randomly distributed into either a control or a 
melatonin administration group. Littermates were kept together to avoid fighting among different litters. 
For a two month period we administered nightly, either melatonin (stock solution: I mg/ml ethanol 
stored at -70 C; working solution: diluted to 20% ) or a control (20% ethanol and 80% salt water) using 
the subcutaneous route of injection using a 24 c.c. needle. In order to assure that the mice would receive 
adequate amounts of melatonin, two daily doses were given, one at 5 p.m. and the other at 10 p.m. from 
June 22,1995 to August 15,1995. The melatonin treatment group received 20 Ilg of melatonin in 20% 
ethanol, while controls were injected with 20% ethanol in a saline solution. Upon completion of the 
experiment the animals were decapitated in total silence( to avoid elevated levels of ACTH which would 
cause corticosterone levels to rise) and blood was collected from each animal in order to obtain the blood 
plasma. Measurement of testosterone and corticosterone levels in each of the plasma samples were found 
by radioimmuno assay (commercial kit; DPC, Los Angeles, CA). 
RESULTS 
Throughout the experiment we lost many mice in the melatonin group to fighting that occurred within 
the cages, because of this we did not have enough of a sample size to adequately measure testosterone or 
corticosterone levels in both the normal melatonin administered group and the PEPCK-hGH melatonin 
and control administered groups; therefore; their values were not included in the results. However, there 
was enough ofa sample in the normal control and PEPCK-bGH (control and melatonin) groups for 
analysis (Fig. I). We found that testosterone was lower in the PEPCK-bGH line (control and melatonin) 
groups as compared to the normal control group. Corticosterone levels were higher in the PEPCK-bGH ( 
control and melatonin) groups than in the normal control group. Despite melatonin treatment 
corticosterone and testosterone levels remained constant between both groups ofPEPCK-bGH (control 
and melatonin) mice. 
MELATONIN GROUP 
ijllEEc~s!immj 
T 
t£~J!~miQE~lBJI':Hll
01/11/95 
miiWJl$;i[QS:IDIRfijE
4.06 
@':Wil~;f@!mtlf!'i:f>~ieKI:NEiiHlg 
128.4 
T 01/19/95 1.59 173.4 
N 01/19/95 .414 410.5 
N 01/19/95 3.29 68.83 
i;jflll:e~gb'Ga:
T 
;;;;%llAlmI()lt!il~m1l!:
12/20/94 
ffj@m._sJtllt(l)NEliii 
1.56 
i:Mii;icKiB;mJiet1$Wl!iIfiBiii;iii 
180.1 
T 12/20/94 1.49 365.1 
T 02/14/95 1.65 192.8 
T 2/14/95 6.08 211 .6 
N 2/14/95 .252 136.8 
T 02/22/95 .317 300.7 
T 02/22/95 .306 175.9 
T 02/22/95 3.32 190.0 
T = Transgenic 
N = Normal 
CONTROL GROUP 
;';:mili::E-eel\fliGll@WiE\ult1fiE;1i)I{iBmwJ))iiI mjf~SI~$_().i'i ;ic()IIDtc$m.l[R~.;i 
T 01/11/95 .581 20.4 
T 10/24/94 .555 49.8 
T 09/15/94 1.41 280.0 
T 09/15/94 6.56 159.1 
T 02/15/95 9.82 103.0 
T 02/15/95 3.9 216.7 
T 02/15/95 4.26 129.6 
N 1/11/95 .852 98 
N 1/11/95 10 193.9 
N 1/11/95 .486 43.4 
N 10/24/94 .555 330.6 
N 9/15/94 .454 52.6 
N 2/15/95 8.3 32 
N 2/15/95 .52 50.34 
If:j'JiiEi_4iG'I@!;:;iiifilmmi,QEil.lllmi'Will.s!l1iST\:EgfjB!!:l!.(lIfjlml<Zn$mllllfiNJ.ll1"j 
T 01/03/95 2.31 148.8 
T 01/03/95 .42 183.1 
T 01/02/95 2.09 225.4 
T 01/02/95 1.33 132.5 
T 02/18/95 .364 112.6 
T 02/18/95 1.62 295.7 
T 02/18/95 1.55 110.0 
T 01/25195 .227 580.5 
T 01/05195 4.1 347.0 
T 01/05195 6.12 224.0 
N 01/03/95 .69 20.9 
N 01/02/95 18.3 40.0 
N 01/05195 20.7 25.1 
N 01/25195 12.03 38.2 
N 01/25195 12.36 67.0 
N 01/25195 8.91 113.8 
N 01/25195 5.33 93.0 
N 01/05195 1.03 91.5 
T = Transgemc 
N =Normal 
Effects Of Melatonin Treatment On Corticosterone And Testosterone Levels In Plasma Of 
Normal and PEPCK-bGH Mice 
(Fig. 1) 
UflllMiiNHi.GH;V 236 (10) ± 45.6 230.9 (8) ±27.7 2.01 (10) ±0.58 2.1 (8) ±0.7 
( ) = Sample size 
Students "t" test 
PEPCK-bGH Corticosterone (Conirol and Melatonin groups) = .293 
PEPCK-bGH Testosterone (Control and Melatonin groups) = .297 
PEPCK-bGH and Normal Corticosterone (Control Groups) = 12.65 * 
PEPCK-bGH and Normal Testosterone (control Groups) = 9.31 * 
* Statistically Significant (greater then 2.1) 
As one can see by the "t" tests performed, the only significant numbers occurred between the control 
populations. Meaning that the mice tested naturally have different levels of testosterone and 
corticosterone. 
DISCUSSION 
The daily injections ofmelatonin at 5 p.m. and again at I0 p.m. seemed to have little effect on the mice 
being tested. Since melatonin is known to decrease levels of testosterone, we would expect to find 
testosterone levels in the PEPCK-bGH control group to be higher than those in the PEPCK-bGH 
melatonin administered group. This was not the case, instead testosterone levels were slightly higher in 
the PEPCK-bGH melatonin administered group than in PEPCK-bGH controls, which is a good 
indication that the experiment was not successful in determining the role melatonin plays in the aging 
process. In measuring corticosterone levels there was no differences in the plasma concentrations 
between PEPCK-bGH control or PEPCK-bGH melatonin groups. The conclusion that corticosterone 
levels are unaffected by melatonin should not be assumed, since the first half ofour experiment was 
inconclusive. A few areas which should be addressed in future experiments include; I.) Determining the 
ideal melatonin dosage. Perhaps higher doses greater then 20 g that was used in this experiment is 
needed. 2.) Longer experimentation time. Since our experiment lasted roughly two months, it may not 
have been enough time for tissue change or for differences in testosterone/cortocosterone levels to occur. 
3.) The route of melatonin administration that we selected may not have been the ideal route. Perhaps 
placing melatonin in the drinking water during the dark phase of the circadian sleep/wake cycle instead 
of subcutaneous injections would have been more effective. It is clear that under the experimental 
situation and parameters that we used to study the effects of melatonin on the aging process, it was 
inconclusive. 
We started out with 25 transgenic mice PEPCK-hGH(7), PEPCK-bGH (18) and 23 normal mice. At the 
end of the experiment we lost (5) PEPCK-hGH from the melatonin group, (9) normal from the 
melatonin group. For lack of numbers the normal melatonin group and the PEPCK-hGH (melatonin and 
control) groups were discarded from being analyzed. With our experiment being inconclusive, 
additional research is needed to find out the true effect melatonin has on the aging process in mice 
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